This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Chelsea Therapeutics' CEO Presents FDA Advisory Committee Update - Conference Call (Transcript)

Stocks in this article: CHTP

Chelsea Therapeutics International Ltd. ( CHTP)

Special Call

February 23, 2012 5:30 pm ET


Kathryn McNeil – Head-Investor & Media Relations

Simon Pedder – President & Chief Executive Officer

William D. Schwieterman – Chief Medical Officer

William B. White – Chief, Hypertension and Clinical Pharmacology Division & Professor, Department of Medicine, University of Connecticut Health Center


Robyn Karnauskas – Analyst, Deutsche Bank Securities, Inc.

Jonathan M. Eckard – Analyst, Leerink Swann LLC

Liana Moussatos – Analyst, Wedbush Securities, Inc.

Juan F. Sanchez – Analyst, Ladenburg Thalmann Securities

David S. Moskowitz – Analyst, ROTH Capital Partners LLC

Martin Shkreli – General Partner, MSMB Capital Management LLC



Good day, ladies and gentlemen, and welcome to Chelsea Therapeutics’ FDA Advisory Committee Update Conference Call. At this time, all participants are in a listen-only mode. Later, we’ll conduct a question-and-answer session, and instructions will be given at that time. (Operator Instructions) As a reminder, this conference call may be being recorded.

I would now like to hand the conference over to Ms. Kate McNeil. Ma’am, you may begin.

Kathryn McNeil

Thank you. Good afternoon, everyone, and thank you for joining us to discuss today’s meeting of the Cardiovascular and Renal Drugs Advisory Committee regarding NORTHERA NDA. Joining me from Chelsea is Dr. Simon Pedder, President and Chief Executive Officer; Dr. Bill Schwieterman, our Chief Medical Officer; Dr. Art Hewitt, our Chief Scientific Officer; and Joe Oliveto, our Chief Operating Officer.

We’re also joined today by Dr. Mark Stacy, Professor of Neurology at Duke Institute for Brain Sciences and Dr. William White, Chief of the Hypertension and Clinical Pharmacology Division at the University of Connecticut Health Center.

1 of 3

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs